Standard therapy for glioblastoma--a review of where we are
- PMID: 20885105
- DOI: 10.2176/nmc.50.713
Standard therapy for glioblastoma--a review of where we are
Abstract
Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat. The current standard therapy includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide. However, recurrence is quite common, so we continue to search for more effective treatments both for initial therapy and at the time of recurrence. This article will review the current standard of care and recent advances in therapy for newly-diagnosed and recurrent glioblastomas, based on the most authoritative guidelines, the National Cancer Institute's comprehensive cancer database Physician Data Query (PDQ®), and the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for central nervous system cancers (V.1.2010), to elucidate the current position and in what direction we are advancing.
Similar articles
-
Recent advances in therapy for glioblastoma.Arch Neurol. 2010 Mar;67(3):279-83. doi: 10.1001/archneurol.2010.5. Arch Neurol. 2010. PMID: 20212224 Review.
-
Status quo--standard-of-care medical and radiation therapy for glioblastoma.Cancer J. 2012 Jan-Feb;18(1):12-9. doi: 10.1097/PPO.0b013e318244d7eb. Cancer J. 2012. PMID: 22290252 Review.
-
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.Clin Neurosurg. 2008;55:165-71. Clin Neurosurg. 2008. PMID: 19248684 No abstract available.
-
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Oncotarget. 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297. Oncotarget. 2015. PMID: 26423602 Free PMC article.
-
[Temozolomide in patients with a glioblastoma multiforme: new developments].Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8. Ned Tijdschr Geneeskd. 2005. PMID: 15997689 Dutch.
Cited by
-
Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.Am J Cancer Res. 2021 Apr 15;11(4):1148-1169. eCollection 2021. Am J Cancer Res. 2021. PMID: 33948351 Free PMC article.
-
Advances in epigenetic glioblastoma therapy.Oncotarget. 2017 Mar 14;8(11):18577-18589. doi: 10.18632/oncotarget.14612. Oncotarget. 2017. PMID: 28099914 Free PMC article. Review.
-
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.Sci Rep. 2016 Dec 21;6:39743. doi: 10.1038/srep39743. Sci Rep. 2016. PMID: 28000777 Free PMC article.
-
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.Cancer Gene Ther. 2012 Aug;19(8):523-9. doi: 10.1038/cgt.2012.25. Epub 2012 May 25. Cancer Gene Ther. 2012. PMID: 22627392 Free PMC article.
-
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas.Front Oncol. 2013 Mar 4;3:43. doi: 10.3389/fonc.2013.00043. eCollection 2013. Front Oncol. 2013. PMID: 23459853 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical